

## SEQUENCE LISTING

&lt;110&gt; Bayer HealthCare AG

&lt;120&gt; Diagnostics and Therapeutics for Diseases Associated with Peroxisome Proliferative Activated Receptor alpha (PPARA)

&lt;130&gt; BHC 04 01 091

&lt;160&gt; 5

&lt;170&gt; PatentIn version 3.2

&lt;210&gt; 1

&lt;211&gt; 1850

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

ggcccaggct	gaagctcagg	gccctgtctg	ctctgtggac	tcaacagttt	gtggcaagac	60
aagctcagaa	ctgagaagct	gtcaccacag	ttctggaggc	tgggaagttc	aagatcaaag	120
tgccagcaga	ttcagtgtca	tgtgaggacg	tgcttcctgc	ttcatagata	agagcttgg	180
gctcggcgca	caaccagcac	catctggtcg	cgatggtgg	cacggaaagc	ccactctgcc	240
ccctctcccc	actcgaggcc	ggcgatctag	agagcccg	tttgaagag	ttcctgcaag	300
aaatggaaaa	catccaagag	atttcgcaat	ccatcgccga	ggatagttct	ggaagctttg	360
gctttacgga	ataccagtat	tttaggaagct	gtcctggctc	agatggctcg	gtcatcacgg	420
acacgctttc	accagcttcg	agcccccct	cggtgactta	tcctgtggtc	cccgccagcg	480
tggacgagtc	tcccagtgg	gcattgaaca	tcgaatgtag	aatctgcggg	gacaaggcct	540
caggctatca	ttacggagtc	cacgcgtgt	aaggctgcaa	gggcttcttt	cggcgaacga	600
ttcgactcaa	gctgggttat	gacaagtgcg	accgcagctg	caagatccag	aaaaagaaca	660
gaaacaaaatg	ccagtattgt	cgatttaca	agtgccttc	tgtcggtat	tcacacaaacg	720
cgattcg	tggacgaatg	ccaagatctg	agaaagcaaa	actgaaagca	gaaattctt	780
cctgtgaaca	tgacatagaa	gattctgaaa	ctgcagatct	caaatctctg	gccaaagagaa	840
tctacgag	ctacttgaag	aacttcaaca	tgaacaaggt	caaagccgg	gtcatcctct	900
caggaaaggc	cagtaacaat	ccacctttt	tcatacatga	tatggagaca	ctgtgtatgg	960
ctgagaagac	gctggtgcc	aagctgg	ccaatggcat	ccagaacaag	gaggcggagg	1020
tccgcattt	tcactgctgc	cagtgcacgt	cagtggagac	cgtcacggag	ctcacggaaat	1080
tcgccaaggc	catcccaggc	ttcgcaaact	tggacctgaa	cgtcaagt	acattgctaa	1140
aatacggagt	ttatgaggcc	atattcgcc	tgctgtctc	tgtatgaac	aaagacggga	1200
tgctggtagc	gtatggaaat	gggttataa	ctcgtgaatt	cctaaaaagc	ctaaggaaac	1260
cgttctgt	tatcatggaa	cccaagttt	atttgc	gaagttcaat	gcactggAAC	1320
tggatgacag	tgatatctcc	ctttttgtgg	ctgctatcat	ttgctgtgg	gatcgtcctg	1380
gccttctaaa	cgtaggacac	attgaaaaaa	tgcaggaggg	tattgtacat	gtgctcagac	1440
tccacctgca	gagcaaccac	ccggacgata	tctttctt	cccaaaactt	cttcaaaaaaa	1500
tggcagac	ccggcagctg	gtgacggagc	atgcgcagct	ggtgcagatc	atcaagaaga	1560
cggagtcg	tgctgcgt	cacccgtac	tgcaggagat	ctacaggac	atgtactgag	1620
ttccttcaga	tcagccacac	cttttccagg	agttctgaag	ctgacagcac	tacaaaggag	1680
acgggggagc	agcacgattt	tgcacaaata	tccaccactt	taaccttaga	gcttggacag	1740
tctgagctgt	aggtaaccgg	catattattc	catactttt	tttaaccag	tacttctaag	1800
agcatagaac	tcaaata	gctgg	ctaatctcag	gactggaaag		1850

<210> 2  
<211> 468  
<212> PRT  
<213> Homo sapiens  
<400> 2

Met Val Asp Thr Glu Ser Pro Leu Cys Pro Leu Ser Pro Leu Glu Ala  
1 5 10 15  
Gly Asp Leu Glu Ser Pro Leu Ser Glu Glu Phe Leu Gln Glu Met Gly  
20 25 30  
Asn Ile Gln Glu Ile Ser Gln Ser Ile Gly Glu Asp Ser Ser Gly Ser  
35 40 45  
Phe Gly Phe Thr Glu Tyr Gln Tyr Leu Gly Ser Cys Pro Gly Ser Asp  
50 55 60  
Gly Ser Val Ile Thr Asp Thr Leu Ser Pro Ala Ser Ser Pro Ser Ser  
65 70 75 80  
Val Thr Tyr Pro Val Val Pro Gly Ser Val Asp Glu Ser Pro Ser Gly  
85 90 95  
Ala Leu Asn Ile Glu Cys Arg Ile Cys Gly Asp Lys Ala Ser Gly Tyr  
100 105 110  
His Tyr Gly Val His Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg  
115 120 125  
Thr Ile Arg Leu Lys Leu Val Tyr Asp Lys Cys Asp Arg Ser Cys Lys  
130 135 140  
Ile Gln Lys Lys Asn Arg Asn Lys Cys Gln Tyr Cys Arg Phe His Lys  
145 150 155 160  
Cys Leu Ser Val Gly Met Ser His Asn Ala Ile Arg Phe Gly Arg Met  
165 170 175  
Pro Arg Ser Glu Lys Ala Lys Leu Lys Ala Glu Ile Leu Thr Cys Glu  
180 185 190  
His Asp Ile Glu Asp Ser Glu Thr Ala Asp Leu Lys Ser Leu Ala Lys  
195 200 205  
Arg Ile Tyr Glu Ala Tyr Leu Lys Asn Phe Asn Met Asn Lys Val Lys  
210 215 220  
Ala Arg Val Ile Leu Ser Gly Lys Ala Ser Asn Asn Pro Pro Phe Val  
225 230 235 240  
Ile His Asp Met Glu Thr Leu Cys Met Ala Glu Lys Thr Leu Val Ala  
245 250 255  
Lys Leu Val Ala Asn Gly Ile Gln Asn Lys Glu Ala Glu Val Arg Ile  
260 265 270  
Phe His Cys Cys Gln Cys Thr Ser Val Glu Thr Val Thr Glu Leu Thr  
275 280 285  
Glu Phe Ala Lys Ala Ile Pro Gly Phe Ala Asn Leu Asp Leu Asn Asp  
290 295 300  
Gln Val Thr Leu Leu Lys Tyr Gly Val Tyr Glu Ala Ile Phe Ala Met  
305 310 315 320

- 3 -

Leu Ser Ser Val Met Asn Lys Asp Gly Met Leu Val Ala Tyr Gly Asn  
325 330 335  
Gly Phe Ile Thr Arg Glu Phe Leu Lys Ser Leu Arg Lys Pro Phe Cys  
340 345 350  
Asp Ile Met Glu Pro Lys Phe Asp Phe Ala Met Lys Phe Asn Ala Leu  
355 360 365  
Glu Leu Asp Asp Ser Asp Ile Ser Leu Phe Val Ala Ala Ile Ile Cys  
370 375 380  
Cys Gly Asp Arg Pro Gly Leu Leu Asn Val Gly His Ile Glu Lys Met  
385 390 395 400  
Gln Glu Gly Ile Val His Val Leu Arg Leu His Leu Gln Ser Asn His  
405 410 415  
Pro Asp Asp Ile Phe Leu Phe Pro Lys Leu Leu Gln Lys Met Ala Asp  
420 425 430  
Leu Arg Gln Leu Val Thr Glu His Ala Gln Leu Val Gln Ile Ile Lys  
435 440 445  
Lys Thr Glu Ser Asp Ala Ala Leu His Pro Leu Leu Gln Glu Ile Tyr  
450 455 460  
Arg Asp Met Tyr  
465

&lt;210&gt; 3

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; forward primer

&lt;400&gt; 3

ccaagttga ttttgcctatg aag

23

&lt;210&gt; 4

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; reverse primer

&lt;400&gt; 4

agcagccaca aaaaggaga t

21

&lt;210&gt; 5

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; probe

&lt;400&gt; 5

tcaatgcact ggaactggat gacagtga

28